Dr. Kathryn C. Hourdequin
Claim this profileDartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Studies Skin Cancer
Studies Gastroesophageal Junction Adenocarcinoma
19 reported clinical trials
35 drugs studied
About Kathryn C. Hourdequin
Education:
- Earned an MD from Geisel School of Medicine at Dartmouth in 2009.
- Obtained a PhD in Pharmacology and Toxicology from Dartmouth College in 2009.
Experience:
- Serves as an Assistant Professor of Medicine at the Geisel School of Medicine at Dartmouth.
- Works as a Medical Oncologist at Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center.
- Completed residency in Internal Medicine and fellowship in Hematology/Oncology at Dartmouth-Hitchcock Medical Center.
Area of expertise
1Skin Cancer
Stage IV
Stage III
BRCA1 positive
2Gastroesophageal Junction Adenocarcinoma
Stage IV
BRCA1 positive
BRCA2 positive
Affiliated Hospitals
Clinical Trials Kathryn C. Hourdequin is currently running
Atezolizumab + Chemotherapy
for Neuroendocrine Carcinoma
This trial is testing a new treatment combining an immune-boosting drug with standard chemotherapy for patients with a specific type of aggressive cancer that has spread. The goal is to help the immune system fight the cancer and use chemotherapy to kill cancer cells.
Recruiting1 award Phase 2 & 310 criteria
Olaparib
for Pancreatic Cancer
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting0 awards Phase 232 criteria
More about Kathryn C. Hourdequin
Clinical Trial Related5 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 12 Active Clinical TrialsTreatments Kathryn C. Hourdequin has experience with
- Fluorouracil
- Cisplatin
- Bevacizumab
- Nivolumab
- Ipilimumab
- Irinotecan
Breakdown of trials Kathryn C. Hourdequin has run
Skin Cancer
Gastroesophageal Junction Adenocarcinoma
Pancreatic Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kathryn C. Hourdequin specialize in?
Kathryn C. Hourdequin focuses on Skin Cancer and Gastroesophageal Junction Adenocarcinoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Kathryn C. Hourdequin currently recruiting for clinical trials?
Yes, Kathryn C. Hourdequin is currently recruiting for 12 clinical trials in Lebanon New Hampshire. If you're interested in participating, you should apply.
Are there any treatments that Kathryn C. Hourdequin has studied deeply?
Yes, Kathryn C. Hourdequin has studied treatments such as Fluorouracil, Cisplatin, Bevacizumab.
What is the best way to schedule an appointment with Kathryn C. Hourdequin?
Apply for one of the trials that Kathryn C. Hourdequin is conducting.
What is the office address of Kathryn C. Hourdequin?
The office of Kathryn C. Hourdequin is located at: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire 03756 United States. This is the address for their practice at the Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.